Lyell Immunopharma’s treatment of Stage IIB-IV melanoma was granted FDA orphan status, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LYEL:
- Lyell Immunopharma is presenting nonclinical data at SITC on LYL119
- Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Lyell Immunopharma to evaluate Cellares’ automated manufacturing platform
- Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
- Lyell, Cellares to evaluate automated manufacturing of its CAR T-Cell Therapy
